20.38
0.53 (2.67%)
| Penutupan Terdahulu | 19.85 |
| Buka | 19.82 |
| Jumlah Dagangan | 675,731 |
| Purata Dagangan (3B) | 897,626 |
| Modal Pasaran | 876,773,568 |
| Harga / Pendapatan (P/E TTM) | 43.36 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.11 |
| Harga / Jualan (P/S) | 1.37 |
| Harga / Buku (P/B) | 1.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -14.76% |
| Margin Operasi (TTM) | 4.63% |
| EPS Cair (TTM) | -2.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -46.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 79.70% |
| Nisbah Semasa (MRQ) | 2.41 |
| Aliran Tunai Operasi (OCF TTM) | 175.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 144.75 M |
| Pulangan Atas Aset (ROA TTM) | 3.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Pacira BioSciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.70 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.79% |
| % Dimiliki oleh Institusi | 110.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 38.00 (HC Wainwright & Co., 86.46%) | Beli |
| Median | 34.00 (66.83%) | |
| Rendah | 30.00 (Needham, 47.20%) | Beli |
| Purata | 34.00 (66.83%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 23.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 38.00 (86.46%) | Beli | 23.53 |
| Needham | 09 Jan 2026 | 30.00 (47.20%) | Beli | 23.53 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FROIMSON MARK | - | 21.94 | -500 | -10,970 |
| SLONIN JONATHAN | - | 21.94 | -3,261 | -71,546 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,761 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -82,516 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 21.94 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FROIMSON MARK | Pengarah | 17 Mar 2026 | Jual (-) | 500 | 21.94 | 10,970 |
| SLONIN JONATHAN | Pegawai | 17 Mar 2026 | Jual automatik (-) | 3,261 | 21.94 | 71,546 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors |
| 13 Jan 2026 | Pengumuman | Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets |
| 08 Jan 2026 | Pengumuman | Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues |
| 07 Jan 2026 | Pengumuman | Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences |
| 30 Dec 2025 | Pengumuman | DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |